Oxana Iliach is a Senior Director of Regulatory Strategy at Certara (PA, USA), a biotech company that offers comprehensive solutions for transforming and accelerating drug development. In her spare ...
Rare disease clinical trials are smaller and often use surrogate endpoints, reducing costs but posing unique operational ...
The potential of using artificial intelligence in drug discovery and development has sparked both excitement and skepticism among scientists, investors, and the general public. Researchers have ...
The companies will invest up to $1 billion over five years to support discovery and development powered by artificial ...
Researchers have applied AI and machine learning to every stage of the drug development process. This includes identifying targets in the body, screening potential candidates, designing drug molecules ...
To optimize the final formulation for a drug, it must meet many criteria beyond producing a safe and effective product. For example, it must be stable and amenable to various manufacturing steps, such ...
The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...
Real-World Data and Real-World Evidence (RWD/RWE) have been utilized not only for drug safety assessment but also for ...
The field of cancer research has increasingly focused on the metabolic underpinnings of tumorigenesis, recognizing how the reprogramming of cellular energy ...
Explore key identity management challenges in pharma and biotech SaaS platforms and learn practical solutions for security, compliance, and scalability.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results